Table 1 shows a comprehensive overview of seven clinical trials aimed at studying the efficacy and safety of GLP-1 RA in patients with type 2 diabetes, obesity and cardiovascular diseases. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.